Prompt response of advanced cutaneous squamous cell carcinoma to cemiplimab in a kidney transplant patient under everolimus treatment.

Immune checkpoint inhibitors (ICI) are increasingly used in numerous advanced solid cancers. Nevertheless, the safety and efficacy of ICI in solid organ transplant recipients (SOTR) are unclear, since SOTR are usually excluded from clinical investigations due to their high risk for irreversible allograft rejection.1-4.